Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00266838
Other study ID # UZL OFT-ML 3386
Secondary ID
Status Completed
Phase Phase 1
First received December 16, 2005
Last updated June 24, 2010
Start date July 2006
Est. completion date May 2009

Study information

Verified date December 2005
Source Universitaire Ziekenhuizen Leuven
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicines and Health Products, FAMHP
Study type Interventional

Clinical Trial Summary

The antineoplastic agent Docetaxel (Taxotere®) is approved for the treatment of patients with metastatic and locally advanced breast cancer and other malignancies. There are 2 frequently used schedules of treatment with Docetaxel. Docetaxel can be administered every 3 weeks or in a weekly regimen. The efficacy seems to be similar but the toxicity profile changes. In the standard 3-weekly Docetaxel regimen the dose-limiting side effect is myelosuppression, while in the weekly regimen there is only a mild myelosuppression. On the other hand, weekly Docetaxel has a side effect that is rare in the 3-weekly schedule: epiphora (= tearing eye) caused by dacryostenosis.

The underlying mechanism of dacryostenosis induced by weekly Docetaxel is fibrosis of the lacrimal puncta and canaliculi. Docetaxel has been reported to be secreted in the lacrimal tears. Direct contact between Docetaxel containing tears and the epithelial lining causes chronic inflammation of the mucosa and ultimately fibrosis of the most narrow part of the lacrimal outflow system i.e. the lacrimal puncta and canaliculi.

A surgical treatment is possible for dacryostenosis. In case of subtotal stenosis of the lacrimal canaliculi, silicone intubation of the canaliculi is performed in order to prevent further closure. In the case of complete stenosis, placement of a permanent pyrex glass tube of Jones is required.

To our knowledge, there is no primary prevention for Docetaxel induced dacryostenosis.

The rationale of this randomized double blind interventional study is to investigate the efficacy of corticosteroid versus artificial tears topical eye treatment in patients on a weekly Docetaxel regimen in prevention of dacryostenosis. The dacryotoxic agent Docetaxel in the lacrimal tears will be washed away by the repetitive use of eye drops. In addition, eye drops containing corticosteroids have an anti-inflammatory effect and may further prevent the formation of fibrosis.

A new treatment protocol will be investigated. Two different commercially available eye drops will be compared: dexamethasone sodium phosphate (Maxidex®, Alcon) in one eye of the patient and artificial tears (Lacrystat®, Viatris) in the other eye of the same patient. The study period will start with topical eye treatment from day 1 of cycle 1 and will continue during the administration of chemotherapy, with a final analysis at 26 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date May 2009
Est. primary completion date May 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with locally advanced or metastatic breast cancer receiving weekly Docetaxel chemotherapy with rest weeks in between at regular time intervals. The timing of rest weeks between cycles is not restricted. Examples of allowed regimens are Docetaxel 36 mg/m2 day 1 and 8 every 3 weeks; day 1, 8, 15 every 4 weeks; day 1, 8, 15, 21, 28, 35, 42, 49 every 10 weeks. Dosing and rest weeks can be further modified depending on the clinical situation, but dose intensity should be at least 60 mg/m2 every 3 weeks during the 9 week treatments for eligibility. Combination with other chemotherapy (such as capecitabine) is allowed.

- Capability to administer eye drops (either by patient or companion).

- Written informed consent.

- Age > 18 y

Exclusion Criteria:

- Systemic criteria:

- Previous administration of Docetaxel.

- Pregnancy.

- Eye criteria:

- Ocular surface, corneal, conjunctival or eyelid disease.

- Soft contact lens wearing

- Glaucoma

- Lacrimal criteria:

- Hypersecretion of tears: ocular surface, corneal, conjunctival or eyelid disease.

- Functional blockage of lacrimal drainage without anatomical obstruction (facial nerve palsy, displacement of the lower lacrimal punctum from the lacrimal lake, involutional lower eyelid laxity).

- Anatomical obstruction of lacrimal drainage system:

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Maxidex; Lacrystat
6 times daily, for 20 weeks.

Locations

Country Name City State
Belgium Mombaerts Leuven

Sponsors (1)

Lead Sponsor Collaborator
Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of dacryostenosis 20 weeks No
Primary Grading of dacryostenosis 20 weeks No
Secondary Correlation Docetaxel in lacrimal tear and dacryostenosis 20 weeks No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04833452 - Comparative Study Between Wide and Narrow Fenstrum Endoscopic DCR N/A
Completed NCT02240615 - The Sinopsys Lacrimal Stent for Lacrimal System Repair in Epiphora Phase 0
Suspended NCT03705000 - SLlt Stent II Lacrimal Stent for the Treatment of Nasolacrimal Duct Obstruction N/A
Completed NCT01010659 - The Safety and Efficacy of Lacrimal Silicone Intubation for the Management of Epiphora Phase 4
Recruiting NCT05663684 - Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain? Phase 4
Terminated NCT04229771 - Does Topical Ophthalmic Anesthetic Prior to Probing and Irrigation Decrease Pain? Phase 4
Active, not recruiting NCT02849093 - Optical Coherence Tomography of Ocular Structures in Epiphora and Dry Eye Syndrome. N/A
Withdrawn NCT00824811 - Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel Phase 2
Completed NCT03731143 - Management of Lower Punctal Stenosis. N/A
Active, not recruiting NCT04680078 - Placement of Three Interrupted Sutures After Triangular Three-snip Punctoplasty N/A
Completed NCT01282541 - Determination of the Optimum Delivery Route for Botulinum Toxin A in Patients With Epiphora Phase 2
Completed NCT02503956 - Perforated Punctal Plugs for Treatment of Papillary Conjunctivitis in Otherwise Healthy Patients N/A
Completed NCT04637633 - Topical Cyclosporine-A for Management of Epiphora Phase 2/Phase 3
Withdrawn NCT03266081 - Bupivacaine Epiphora Trial Phase 2
Completed NCT01766232 - Lacrimal Drainage Resistance Study N/A